Zhen-Hao Wu, Yu-Jing An, Zhen-Xing Chu, Xin-Ru Li, An-Yang Hou, Yong-Jun Jiang, Qing-Hai Hu
{"title":"Cost-effectiveness of self-sampling and enhanced strategies for HPV prevention among men who have sex with men in China: a modeling study.","authors":"Zhen-Hao Wu, Yu-Jing An, Zhen-Xing Chu, Xin-Ru Li, An-Yang Hou, Yong-Jun Jiang, Qing-Hai Hu","doi":"10.1186/s12916-025-04131-w","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Human papillomavirus (HPV) testing on self-collected samples (self-sampling) can address the challenges with facility-sampling among men who have sex with men (MSM). However, its cost-effectiveness and effective combination with vaccination must be evaluated, particularly in the absence of national HPV vaccination immunization programs among men.</p><p><strong>Methods: </strong>We constructed a decision-analytic Markov model to assess the cost-effectiveness of the status quo, HPV self-sampling at different intervals, vaccination alone, and HPV self-sampling-vaccination combination based on the incremental cost-effectiveness ratio (ICER), from a healthcare system perspective. Univariate and probabilistic sensitivity analyses were conducted to evaluate the robustness of the proposed model.</p><p><strong>Results: </strong>A lifetime cost-effectiveness analysis on a hypothetical cohort comprising 100,000 MSM aged 12 years at baseline projected that combining screening and vaccination generated incremental costs of US$49,638-219,213 million while accruing 189,881-271,564 quality-adjusted life-years (QALYs) compared with the status quo. Incorporating HPV self-sampling significantly improved the cost-effectiveness of traditional interventions. Remarkably, combining annual HPV self-sampling with nine-valent vaccination proved the most cost-effective at a willingness-to-pay (WTP) threshold three times the Chinese per-capita gross domestic product (GDP). This strategy yielded an ICER of $775 per QALY compared to the status quo and was 55.7% possible to be cost-effective with a WTP threshold three times the per-capita GDP, outperforming other strategies.</p><p><strong>Conclusions: </strong>Implementing annual HPV self-sampling along with nine-valent vaccination is projected to be the most cost-effective among MSM in China. Reducing the costs of HPV self-sampling and vaccination is crucial for guaranteeing that future initiatives produce favorable economic outcomes. These findings provide valuable guidance for formulating policies on HPV prevention among MSM in China.</p>","PeriodicalId":9188,"journal":{"name":"BMC Medicine","volume":"23 1","pages":"362"},"PeriodicalIF":7.0000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12217994/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12916-025-04131-w","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Human papillomavirus (HPV) testing on self-collected samples (self-sampling) can address the challenges with facility-sampling among men who have sex with men (MSM). However, its cost-effectiveness and effective combination with vaccination must be evaluated, particularly in the absence of national HPV vaccination immunization programs among men.
Methods: We constructed a decision-analytic Markov model to assess the cost-effectiveness of the status quo, HPV self-sampling at different intervals, vaccination alone, and HPV self-sampling-vaccination combination based on the incremental cost-effectiveness ratio (ICER), from a healthcare system perspective. Univariate and probabilistic sensitivity analyses were conducted to evaluate the robustness of the proposed model.
Results: A lifetime cost-effectiveness analysis on a hypothetical cohort comprising 100,000 MSM aged 12 years at baseline projected that combining screening and vaccination generated incremental costs of US$49,638-219,213 million while accruing 189,881-271,564 quality-adjusted life-years (QALYs) compared with the status quo. Incorporating HPV self-sampling significantly improved the cost-effectiveness of traditional interventions. Remarkably, combining annual HPV self-sampling with nine-valent vaccination proved the most cost-effective at a willingness-to-pay (WTP) threshold three times the Chinese per-capita gross domestic product (GDP). This strategy yielded an ICER of $775 per QALY compared to the status quo and was 55.7% possible to be cost-effective with a WTP threshold three times the per-capita GDP, outperforming other strategies.
Conclusions: Implementing annual HPV self-sampling along with nine-valent vaccination is projected to be the most cost-effective among MSM in China. Reducing the costs of HPV self-sampling and vaccination is crucial for guaranteeing that future initiatives produce favorable economic outcomes. These findings provide valuable guidance for formulating policies on HPV prevention among MSM in China.
期刊介绍:
BMC Medicine is an open access, transparent peer-reviewed general medical journal. It is the flagship journal of the BMC series and publishes outstanding and influential research in various areas including clinical practice, translational medicine, medical and health advances, public health, global health, policy, and general topics of interest to the biomedical and sociomedical professional communities. In addition to research articles, the journal also publishes stimulating debates, reviews, unique forum articles, and concise tutorials. All articles published in BMC Medicine are included in various databases such as Biological Abstracts, BIOSIS, CAS, Citebase, Current contents, DOAJ, Embase, MEDLINE, PubMed, Science Citation Index Expanded, OAIster, SCImago, Scopus, SOCOLAR, and Zetoc.